Market News AIOpen the app

AstraZeneca got the green light in the US and Europe for two new treatments for rare diseases and bladder cancer.

TrialRead the original at Benzinga
Good for AZN

AstraZeneca won approvals for two treatments, backed by studies showing improved patient outcomes. The approvals cover specific groups, and Klygefa is still under review in China and other countries.

AZN · AstraZeneca Plc

AI read · Good for AZN

The AI's read

These approvals give AstraZeneca new treatment options for people with two serious illnesses, including some patients who cannot take cisplatin. The bladder-cancer study found fewer serious outcomes with the new treatment plan. Klygefa still awaits decisions in China and other countries, limiting its reach there for now.

Get alerts for AZN

Follow AstraZeneca Plc (AZN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for AZN
Free on the App Store and Google Play, or on the web.